Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors
暂无分享,去创建一个
Kwang Kim | Keun Woo Lee | Shalini John | Sundarapandian Thangapandian | Mahreen Arooj | Jong Hong | M. Arooj | Keun Woo Lee | S. Thangapandian | Jong-Chan Hong | K. Kim | Shalini John | Mahreen Arooj
[1] W Patrick Walters,et al. Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.
[2] K. Nakao,et al. Molecular cloning of a novel mouse aspartic protease‐like protein that is expressed abundantly in the kidney , 1997, FEBS letters.
[3] A. Gradman,et al. Current concepts: renin inhibition in the treatment of hypertension. , 2008, Current opinion in pharmacology.
[4] S. Durdağı,et al. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. , 2009, European journal of medicinal chemistry.
[5] W. Watt,et al. Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues. , 1986, Journal of medicinal chemistry.
[6] Thangapandian Sundarapandian,et al. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery , 2010 .
[7] Kavitha Bharatham,et al. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors. , 2007, Journal of molecular graphics & modelling.
[8] J. Staessen,et al. Oral renin inhibitors , 2006, The Lancet.
[9] Steven L. Dixon,et al. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition , 2003, J. Chem. Inf. Comput. Sci..
[10] Hans-Dieter Höltje,et al. Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists. , 2002, Molecular pharmacology.
[11] Y. Kurogi,et al. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. , 2001, Current medicinal chemistry.
[12] A. Ben Wagner,et al. SciFinder Scholar 2006: An Empirical Analysis of Research Topic Query Processing , 2006, J. Chem. Inf. Model..
[13] C. Oefner,et al. Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site. , 1999, Bioorganic & medicinal chemistry letters.
[14] Serdar Durdagi,et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. , 2010, Journal of molecular graphics & modelling.
[15] Sugunadevi Sakkiah,et al. Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. , 2011, European journal of medicinal chemistry.
[16] Wei Li,et al. Investigation of binding features: Effects on the interaction between CYP2A6 and inhibitors , 2010, J. Comput. Chem..
[17] A. Gradman,et al. Renin inhibition in hypertension. , 2008, Journal of the American College of Cardiology.
[18] L. Prade,et al. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. , 2009, Journal of medicinal chemistry.
[19] R. Jiao,et al. Anti-hypertensive nutraceuticals and functional foods. , 2009, Journal of agricultural and food chemistry.
[20] N. Hollenberg,et al. Renin inhibition: what are the therapeutic opportunities? , 2005, Journal of the American Society of Nephrology : JASN.
[21] Jianpeng Ma,et al. Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands , 2008, Proteins.
[22] Kenneth M Merz,et al. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. , 2003, Journal of medicinal chemistry.
[23] N. Powell,et al. Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[24] Parr,et al. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.
[25] The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin. , 2009, Bioorganic & medicinal chemistry letters.
[26] René Thomsen,et al. MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.
[27] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[28] S. Vadivelan,et al. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies. , 2009, European journal of medicinal chemistry.
[29] M. Neves,et al. An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. , 2009, European journal of medicinal chemistry.
[30] S. Sakkiah,et al. Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors. , 2011, European journal of medicinal chemistry.
[31] R. Sarma,et al. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors. , 2008, European journal of medicinal chemistry.
[32] J. Pople,et al. Self-consistent molecular orbital methods. 21. Small split-valence basis sets for first-row elements , 2002 .
[33] Sugunadevi Sakkiah,et al. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. , 2010, Journal of molecular graphics & modelling.
[34] Evan Bolton,et al. An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..
[35] G. Nguyen,et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.
[36] Nilesh R. Tawari,et al. Pharmacophore mapping and electronic feature analysis for a series of nitroaromatic compounds with antitubercular activity , 2009, J. Comput. Chem..
[37] A. Becke. A New Mixing of Hartree-Fock and Local Density-Functional Theories , 1993 .
[38] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[39] Om Silakari,et al. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. , 2010, European journal of medicinal chemistry.
[40] Maurizio Fermeglia,et al. Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. , 2009, Journal of medicinal chemistry.
[41] Thierry Langer,et al. Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) Inhibitors , 2006, J. Chem. Inf. Model..
[42] Mark S. Gordon,et al. Self-consistent molecular-orbital methods. 22. Small split-valence basis sets for second-row elements , 1980 .
[43] Keun Woo Lee,et al. Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase , 2011, J. Chem. Inf. Model..
[44] A. Boucekkine,et al. DFT study of conjugated biheterocyclic oligomers exhibiting a very low HOMO–LUMO energy gap , 2004 .
[45] N. Cohen,et al. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. , 2007, Chemical biology & drug design.
[46] Alice Stanton,et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.
[47] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[48] S. Sakkiah,et al. Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies. , 2010, European journal of medicinal chemistry.